Effects of bicalutamide: A Synthesis of Findings from 23 Studies

  1. Home
  2. Effects of bicalutamide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of bicalutamide: A Synthesis of Findings from 23 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of bicalutamide: A Synthesis of Findings from 23 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Bicalutamide is a non-steroidal antiandrogen that is used to treat prostate cancer. 22 Bicalutamide works by blocking the androgen receptor (AR), which is a protein that is found in prostate cancer cells. 16 When bicalutamide binds to the AR, it prevents the AR from binding to androgens. 16 This prevents the androgen from stimulating the growth of prostate cancer cells. 16 Some studies have found that bicalutamide can induce the production of enzymes in the liver. 22 These enzymes can affect the metabolism of other drugs, which could potentially lead to drug interactions. 22 Bicalutamide has also been shown to have effects on bone mineral density and body composition. 18 Bicalutamide has been shown to decrease bone mineral density in rats. 15 However, these changes are considered to have little clinical relevance. 22 In humans, bicalutamide does not produce enzyme induction at clinically relevant dose levels. 22

Benefits and Risks

Benefits Summary

Bicalutamide is an effective drug for treating prostate cancer. 23 It can help to slow the growth of the cancer and may even help to shrink the tumor. 16 Bicalutamide is generally safe, and side effects are relatively mild. 23 Bicalutamide may also be used in combination with other drugs to improve the effectiveness of treatment. 16 , 12 , 3

Risks Summary

Bicalutamide can cause side effects, such as nausea, vomiting, loss of appetite, fatigue, rash, headache, and increased liver enzymes. 23 , 22 , 9 Bicalutamide can also decrease bone mineral density. 18 , 15 Bicalutamide can also cause liver tumors and thyroid tumors. 22 Bicalutamide can interact with other drugs. 16 , 14

Comparison Between Studies

Commonalities

Many studies have shown that bicalutamide is an effective treatment for prostate cancer. 23 , 1 , 16 , 17 , 12 , 11 Studies have also shown that bicalutamide is generally safe. 23 , 18 , 15 , 19 , 14 , 1

Differences

The side effects and effectiveness of bicalutamide vary depending on the study. 23 , 22 , 9 , 18 , 15 , 19 , 14 This is because the patients included in the studies and the study methods differ. 23 , 22 , 9 , 18 , 15 , 19 , 14

Consistency and Contradictions

Many studies have shown that bicalutamide is an effective treatment for prostate cancer. 23 , 1 , 16 , 17 , 12 , 11 However, the side effects and effectiveness of bicalutamide can vary depending on the study. 23 , 22 , 9 , 18 , 15 , 19 , 14 This is because the patients included in the studies and the study methods differ. 23 , 22 , 9 , 18 , 15 , 19 , 14 Therefore, it is important to discuss the risks and benefits of bicalutamide with a doctor before taking it.

Real-World Application Considerations

Bicalutamide is an effective drug for treating prostate cancer. 23 , 1 , 16 , 17 , 12 , 11 However, bicalutamide can cause a number of side effects. 23 , 22 , 9 , 18 , 15 , 19 , 14 It is important to discuss the risks and benefits of bicalutamide with a doctor before taking it. 23 , 22 , 9 , 18 , 15 , 19 , 14

Limitations of Current Research

More research is needed on bicalutamide. 23 , 22 , 9 , 18 , 15 , 19 , 14 More research is needed on the side effects and effectiveness of bicalutamide. 23 , 22 , 9 , 18 , 15 , 19 , 14

Future Research Directions

More research is needed to better understand the side effects and effectiveness of bicalutamide. 23 , 22 , 9 , 18 , 15 , 19 , 14 In particular, more research is needed on how bicalutamide affects liver enzymes, bone mineral density, and interactions with other drugs. 22 , 9 , 18 , 15 , 16 , 14

Conclusion

Bicalutamide is an effective drug for treating prostate cancer. 23 , 1 , 16 , 17 , 12 , 11 It is important to discuss the risks and benefits of bicalutamide with a doctor before taking it. 23 , 22 , 9 , 18 , 15 , 19 , 14 More research is needed on bicalutamide. 23 , 22 , 9 , 18 , 15 , 19 , 14 This will help to ensure that bicalutamide is used safely and effectively to treat prostate cancer.

Literature analysis of 23 papers
Positive Content
18
Neutral Content
2
Negative Content
3
Article Type
2
0
0
0
22
1.

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

Author: BalesG T, ChodakG W

Prostate cancer treatment

Bicalutamide, a new antiandrogen, has been shown to be as effective as castration in treating advanced prostate cancer, with potentially fewer side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.

Author: TreeAlison, GriffinClare, SyndikusIsabel, BirtleAlison, ChoudhuryAnanya, GrahamJohn, FergusonCatherine, KhooVincent, MalikZafar, O'SullivanJoe, PanadesMiguel, ParkerChris, RimmerYvonne, ScraseChristopher, StaffurthJohn, DearnaleyDavid, HallEmma,

Prostate cancer treatment

This study compared the efficacy and side effects of two hormone therapies (LHRHa and bicalutamide) in patients with localized prostate cancer who received moderately hypofractionated radiation therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.

Author: KimKyoung-Ah, ChaYu-Jung, LeeHae-Mi, JooHyun-Jin, ParkJi-Young

Treatment failure

Bicalutamide is an oral non-steroidal anti-androgen used in the treatment of prostate cancer. This study evaluated the roles of ABCB1 and ABCG2 genetic polymorphisms in the pharmacokinetics of bicalutamide in humans.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.

Author: LinT-H, IzumiK, LeeS O, LinW-J, YehS, ChangC

Prostate cancer treatment
PCa metastasis promotion

Anti-androgens used in androgen deprivation therapy (ADT) may promote prostate cancer (PCa) metastasis by enhancing macrophage migration to PCa cells.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.

Author: HamWon Sik, ChoNam Hoon, KimWon Tae, JuHee Jeong, LeeJin Sun, ChoiYoung Deuk

Prostate cancer treatment

This study analyzed the expression of PTEN, HER2, and neuroendocrine differentiation after bicalutamide monotherapy in patients with advanced prostate cancer. Understanding these molecular changes is important for evaluating the efficacy of second-line therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Author: GravinaGiovanni Luca, FestucciaClaudio, MillimaggiDanilo, DoloVincenza, TomboliniVincenzo, de VitoMariano, VicentiniCarlo, BolognaMauro

AR expression
PSA expression
cell survival
proliferation

Demethylating agents, such as Aza-CR, can reactivate androgen receptor (AR) expression in androgen-independent prostate cancer cells. This suggests that epigenetic reactivation of AR may be a potential therapeutic target for bicalutamide therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.

Author: FestucciaClaudio, GravinaGiovanni Luca, MuziPaola, PomanteRoberto, VenturaLuca, RicevutoEnrico, VicentiniCarlo, BolognaMauro

Inhibited prostate cancer growth

Bicalutamide treatment induced TrkA and TrkC and reduced p75NTR expression. A therapeutical effect of CEP701 was seen in all culture conditions, and bicalutamide seemed to sensitize prostate cancer cells to the effects of a pan TrkA inhibitor CEP701.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodelling, and bone biomechanics in healthy rats.

Author: LefortMar, Díaz CurielManuel, CarrascalMaría-Teresa, Méndez-DávilaCioly, de la PiedraConcepción

Bone mineral density reduction

This study analyzed the effects of bicalutamide on bone mineral density (BMD) and compared them to the effects of orchidectomy. The study found that bicalutamide administration had a negative impact on BMD, similar to orchidectomy. This suggests that bicalutamide may have detrimental effects on bone health.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

Author: FestucciaClaudio, GravinaGiovanni Luca, AngelucciAdriano, MillimaggiDanilo, MuziPaola, VicentiniCarlo, BolognaMauro

Delayed androgen independence

This study investigated the effects of gefitinib and bicalutamide, a combination of an EGFR tyrosine kinase inhibitor and a nonsteroidal antiandrogen, on prostate cancer cells. The combination therapy showed synergistic antitumor effects, reducing the IC50 of both drugs and potentially delaying the onset of androgen independence.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Retracted PublicationCases where a publication has been formally withdrawn due to the discovery of serious errors or misconduct.

Language : English

17.

Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.

Author: KnillováJ, BouchalJ, HlobilkováA, StrnadM, KolárZ

Reduce cell viability

The combination of olomoucine and bicalutamide was more effective than either drug alone in reducing the growth of prostate cancer cells. These drugs may be helpful for treating prostate cancer in the future.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.

Author: SmithMatthew R, GoodeMelissa, ZietmanAnthony L, McGovernFrancis J, LeeHang, FinkelsteinJoel S

Fewer side effects
Increased bone density
Less fat accumulation
Breast enlargement
Breast tenderness

This study compared the effects of leuprolide and bicalutamide on bone mineral density and body composition in men with prostate cancer. The study found that bicalutamide increased bone mineral density and lessened fat accumulation. It also had fewer bothersome side effects than leuprolide.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

20.

Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study.

Author: MorganteE, GradiniR, RealacciM, SaleP, D'EramoG, PerroneG A, CardilloM R, PetrangeliE, RussoM, Di SilverioF

Prostate cancer treatment
Connective tissue increase

Long-term treatment with bicalutamide 50 mg daily has minimal impact on testicular ultrastructure and sperm maturation while effectively controlling androgen-dependent prostatic tumors.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Effects of finasteride and bicalutamide on prostatic blood flow in the rat.

Author: LekåsE, BerghA, DamberJ E

Prostate disease treatment

This study investigated the effects of finasteride and bicalutamide, anti-androgenic drugs, on prostatic blood flow in a rat model.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy.

Author: SolowayM S, SchellhammerP F, SmithJ A, ChodakG W, VogelzangN J, KennealeyG T

Prostate cancer treatment
Well tolerated
Breast pain
Gynecomastia

Bicalutamide (50 mg.) daily was well tolerated and efficacious in treating stage D2 prostate cancer.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.